The Indian Journal of Clinical Biochemistry, published by SPRINGER INDIA, serves as a pivotal platform for researchers and professionals in the field of clinical biochemistry. With an ISSN of 0970-1915 and E-ISSN 0974-0422, this esteemed journal has been disseminating high-quality research since its inception in 1986. As a Q3 ranked journal in Clinical Biochemistry according to the 2023 category quartiles, it occupies a significant position within the realm of biochemistry, genetics, and molecular biology—ranked #61 out of 117 in Scopus. The journal's scope emphasizes the advancement of knowledge and practices in clinical diagnostics, aiming to bridge the gap between laboratory research and clinical application. Positioned in the vibrant academic landscape of India, the Indian Journal of Clinical Biochemistry is a crucial resource for students, researchers, and professionals seeking to stay abreast of the latest trends and innovations in the field, thus fostering the development of clinical biochemistry both nationally and globally.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

Cell Discovery, published by SPRINGERNATURE, is a premier open access journal in the dynamic fields of Biochemistry, Cell Biology, Genetics, and Molecular Biology. Since its inception in 2015, this journal has established itself as a key platform for disseminating high-impact research and is recognized with a Q1 ranking across all its core categories for the year 2023. With its remarkable Scopus rankings—7th in Genetics, 9th in Biochemistry, 13th in Molecular Biology, and 15th in Cell Biology—Cell Discovery positions itself among the elite journals in life sciences, showcasing the most innovative breakthroughs and comprehensive reviews. Based in the United Kingdom, this journal operates under an open access model, ensuring that groundbreaking discoveries are readily available to researchers, professionals, and students around the globe. With a commitment to advancing scientific knowledge, Cell Discovery welcomes contributions that push the frontiers of our understanding in cellular and genetic sciences.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

EUROPEAN JOURNAL OF ENDOCRINOLOGY, published by Oxford University Press, stands as a premier international platform dedicated to advancing research in the burgeoning field of endocrinology, diabetes, and metabolism. Since its inception in 1994, this esteemed journal has gained recognition for its rigorous peer-reviewed articles and innovative studies, evidenced by its impressive Q1 rankings across multiple categories, including Endocrinology and Medicine. With a focus on disseminating critical findings and fostering interdisciplinary collaboration, the journal ranks 33rd out of 244 in Endocrinology, Diabetes, and Metabolism, and 20th out of 128 in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics, positioning it in the top percentiles for researchers worldwide. Although it does not offer open access, the journal remains a vital resource for academics and practitioners alike who seek to stay at the forefront of endocrine research. The EUROPEAN JOURNAL OF ENDOCRINOLOGY continues to push the boundaries of knowledge, driving forward the understanding of complex hormonal functions and their clinical implications.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

METABOLISM-CLINICAL AND EXPERIMENTAL is a premier academic journal published by W B SAUNDERS CO-ELSEVIER INC, with a distinguished history dating back to 1952. This journal serves as a vital repository of knowledge in the fields of Endocrinology, Diabetes, and Metabolism, consistently ranking in the top quartile (Q1) within these categories according to the latest metrics. With an impressive impact factor and recognized for its contributions to Biochemistry, Genetics, and Molecular Biology, it ranks #5 out of 128 in the Scopus database for Endocrinology and #11 out of 244 for Medicine related to Endocrinology, Diabetes, and Metabolism, placing it in the 95th and 96th percentiles, respectively. While the journal does not currently offer open access, it maintains rigorous peer review standards and publishes cutting-edge research that drives forward the understanding of metabolic diseases and clinical practices. By engaging with METABOLISM-CLINICAL AND EXPERIMENTAL, researchers, healthcare professionals, and students can explore groundbreaking advancements and pivotal findings that shape the future of metabolic health.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

Epigenomes is a distinguished open access journal published by MDPI, dedicated to advancing the field of epigenetics and its interdisciplinary connections to biochemistry, genetics, and molecular biology. Since its inception in 2017, this journal has provided a transparent platform for researchers to share their findings, contributing to a deeper understanding of epigenetic mechanisms and their implications in health, toxicology, and mutagenesis. Ranked in the Q2 quartile across multiple categories, including biochemistry and genetics, Epigenomes is recognized for its scholarly contributions, reflected in its notable Scopus rankings. Readers benefit from a wealth of open access articles, fostering innovation and collaboration within the academic community. With its headquarters in Switzerland and an unwavering commitment to scientific rigor, Epigenomes is positioned as a vital resource for researchers, professionals, and students seeking to deepen their insights into the epigenomic landscape.

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.